Phase II trial of nivolumab in patients with unresectable or recurrent thymic carcinoma; PRIMER trial
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 09 Oct 2017
At a glance
- Drugs Nivolumab (Primary)
- Indications Malignant thymoma
- Focus Therapeutic Use
- Acronyms PRIMER
- 03 Oct 2017 Status changed from suspended to active, no longer recruiting.
- 01 Jul 2016 Status changed from not yet recruiting to suspended.
- 09 Jun 2016 New trial record